A5102916529- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Polyomavirus and related diseases
- Chronic Myeloid Leukemia Treatments
- Mesenchymal stem cell research
- Transplantation: Methods and Outcomes
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Renal Transplantation Outcomes and Treatments
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Cytomegalovirus and herpesvirus research
- Immunodeficiency and Autoimmune Disorders
- Antifungal resistance and susceptibility
- Hematological disorders and diagnostics
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Eosinophilic Disorders and Syndromes
- Fungal Infections and Studies
- Childhood Cancer Survivors' Quality of Life
Università Cattolica del Sacro Cuore
2015-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2024
Agostino Gemelli University Polyclinic
2015-2024
Wellesley College
2024
CVS Health (United States)
2024
Advanced Radiation Therapy (United States)
2020
Ospedale Policlinico San Martino
2010-2019
Ankara Numune Eğitim ve Araştırma Hastanesi
2019
Fondazione Roma
2017
Italian Association for Cancer Research
2016
Defining conditioning regimen intensity has become a critical issue for the hemopoietic stem cell transplant (HSCT) community. In present report we propose to define regimens in 3 categories: (1) myeloablative (MA) conditioning, (2) reduced-intensity (RIC), and (3) nonmyeloablative (NMA) conditioning. Assignment these categories is based on duration of cytopenia requirement (SC) support: MA cause irreversible SC support mandatory. NMA minimal cytopenia, can be given also without support. RIC...
Mesenchymal stem cells (MSCs) are found in a variety of tissues, including human bone marrow; secrete hematopoietic cytokines; support progenitors vitro; and possess potent immunosuppressive properties. We hypothesized that cotransplantation culture-expanded MSCs (HSCs) from HLA-identical sibling donors after myeloablative therapy could facilitate engraftment lessen graft-versus-host disease (GVHD); however, the safety feasibility this approach needed to be established. In an open-label,...
Recent studies have shown that long-term survivors of acquired aplastic anemia may be at high risk for malignant diseases. We assessed the cancer after was treated with immunosuppression or bone marrow transplantation and sought to identify factors according treatment. The study population consisted 860 patients by 748 who had received transplants treatment severe anemia. analyzed overall relative in general population. In calculating risk, we excluded myelodysplastic syndromes acute...
This is an analysis of 509 patients with severe aplastic anaemia (SAA) treated in Europe between 1981 and 1986; 218 were by allogeneic bone marrow transplantation (BMT) from HLA identical sibling donors 291 immunosuppressive therapy (IS) antilymphocyte globulin (ALG). The overall actuarial survival was 63% after BMT 61% IS at 6 years. All fulfilled the criteria SAA; however, most a neutrophil count <0.2 × 10 9 /l also had infections haemorrhages. Therefore further subclassification...
Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by posttransplantation high-dose cyclophosphamide (PT-CY): the myeloablative (MA) conditioning consisted of thiotepa, busulfan, fludarabine (n = 35), or total body irradiation (TBI), 15). The median age was 42 years (range, 18-66 years); 23 were in remission, 27 had active disease, and 10 receiving a second allograft. Graft-versus-host disease (GVHD)...
This is an update of a randomized study on antithymocyte globulin (ATG; Thymoglobulin) before transplantation in patients undergoing unmanipulated marrow from unrelated donors. The median follow-up for surviving 5.7 years. At last follow-up, chronic graft-versus-host disease (GVHD) was scored 60% non-ATG and 37% ATG (P=.05), extensive GVHD present 41% 15%, respectively (P=.01). Chronic lung dysfunction diagnosed 51% versus 19% (P=.005). Forced vital capacity decreased significantly with time...
This study was performed to examine the characteristics of transplant activity for patients with myelodysplastic syndromes (MDS) older than 50 years within European Group Blood and Marrow Transplantation, evaluate factors predicting outcome this group patients.We a retrospective multicenter analysis 1,333 MDS age or who received transplantation EBMT since 1998. The median recipient 56 years, 884 (66%) 60 449 (34%) years. There were 811 HLA-matched sibling (61%) 522 (39%) unrelated donor...
We studied 459 consecutive patients with hematologic malignancies, median age 44 years (range, 15 to 71 years), who underwent transplantation grafts from identical sibling donors (SIB; n = 176), matched unrelated (MUD; 43), mismatched (mmUD; cord blood (UCB; 105) or HLA-haploidentical family (HAPLO; 92). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate in the SIB recipients; antithymocyte globulin for MUD, mmUD, UCB post-transplantation...
The genetic basis of myelodysplastic syndromes (MDS) is heterogeneous, and various combinations somatic mutations are associated with different clinical phenotypes outcomes. Whether the MDS influences outcome allogeneic hematopoietic stem-cell transplantation (HSCT) unclear.We studied 401 patients or acute myeloid leukemia (AML) evolving from (MDS/AML). We used massively parallel sequencing to examine tumor samples collected before HSCT for in 34 recurrently mutated genes neoplasms. then...
Recurrently mutated genes and chromosomal abnormalities have been identified in myelodysplastic syndromes (MDS). We aim to integrate these genomic features into disease classification prognostication.We retrospectively enrolled 2,043 patients. Using Bayesian networks Dirichlet processes, we combined mutations 47 with cytogenetic identify genetic associations subgroups. Random-effects Cox proportional hazards multistate modeling was used for developing prognostic models. An independent...
Experience using post-transplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation (HSCT) from matched sibling donors (MSD) or unrelated (UD) is limited and with controversial results. The study aim was to evaluate PT-Cy GVHD post-HSCT MSD UD transplants. We analyzed 423 patients acute leukemia who received alone combination other immunosuppressive (IS) drugs prophylaxis. Seventy-eight (group 1); 204 one IS drug—cyclosporine-A...
The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera (PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) interferon-α (IFN-α) are the most frequently used cytoreductive options ET PV at high risk vascular complications. Myeloproliferative Disorders Research Consortium 112 was an investigator-initiated, phase 3 trial comparing HU pegylated IFN-α (PEG) in treatment-naïve, high-risk ET/PV. primary endpoint complete response...
Despite emergence of novel therapies to treat hematologic malignancies, allogeneic hematopoietic cell transplantation (allo-HCT) remains an essential treatment modality capable curing these diseases. Allo-HCT has been also shown be curative in benign disorders such as aplastic anemia, sickle disease, and thalassemia, among others. Recently, the American Society for Transplantation Cellular Therapy (ASTCT) published standardized definitions recovery, graft rejection, failure, poor function,...